Business Context and Reporting Period
This Form 6-K filing by Can-Fite Biopharma Ltd. covers the month of August 2018, with the report dated August 6, 2018. The filing primarily serves to incorporate by reference a press release regarding a new strategic partnership.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a corporate event rather than financial performance data.
Material Changes
On August 6, 2018, the Company signed a License, Collaboration, and Distribution Agreement with CMS Medical Venture Investment Limited. This agreement covers the commercialization of two of the Company's products in China (including Hong Kong, Macao, and Taiwan):
- Piclidenoson: For the treatment of rheumatoid arthritis and psoriasis.
- Namodenoson: For the treatment of advanced liver cancer and NAFLD/NASH.
Guidance, Outlook, and Risks
The filing incorporates "Forward Looking Statements" from the attached press release but does not detail specific financial guidance or quantitative outlooks within the text of the Form 6-K itself. The primary risk and contingency relate to the execution and success of the new commercialization agreement in the Chinese market.
Investor Verification Checklist
- Verify the specific terms, milestones, and royalty structures of the agreement with CMS Medical Venture Investment Limited in the attached Exhibit 99.1.
- Confirm the regulatory status of Piclidenoson and Namodenoson within the Chinese market.
- Review the full text of the "Forward Looking Statements" in the press release for specific assumptions regarding future commercialization.